Wuppertal, Germany, January 19, 2011 / b3c newswire /– AiCuris today announced that Dr. Marie-Paule Richard has assumed the responsibility of Chief Medical Officer at AiCuris, Germany. Dr. Richard has over 24 years of experience in the pharmaceutical industry in leading global clinical development projects, supervising clinical-regulatory strategies, clinical operations, pharmacovigilance, medical affairs, and managing multicultural and cross-functional teams and departments. She has been responsible for the global development of a large number of anti-infectives and vaccines that she led successfully to international registrations.
After six years at Bristol-Myers Squibb as a medical-marketing Manager, Dr Richard joined Aventis Pharma as European Clinical Project Manager in a French-Japanese joint-venture, then as Director in the global anti-infectives corporate clinical department. In 2000, she joined GlaxoSmithKline in the UK as Sr Director with responsibility for a portfolio of anti-infectives. Thereafter Dr Richard was appointed VP Clinical Development in Sanofi Pasteur France . From 2008, she was a Medical Advisor for several biotech companies in Switzerland and France, and for a Capital Venture Fonds.
Dr. Richard is an M.D., she received her diploma in clinical immunology, pharmacology/ pharmacokinetics, and an MBA from CEDEP-INSEAD.
"We are very pleased to see Dr. Richard join the team at AiCuris as CMO. She has a profound background in infectious diseases and a great development and management expertise", comments AiCuris CEO, Prof. Helga Rübsamen-Schaeff.
"I am extremely happy to join the experienced and highly qualified Development team at AiCuris. The R&D portfolio is very promising and I am thrilled with this opportunity to develop this portfolio further at AiCuris and to bring my competences to the Management Team", adds Dr. Marie-Paule Richard.
About AiCuris - www.aicuris.com
AiCuris GmbH & Co KG (the name is derived from: anti infective cures) is a privately held company located in Wuppertal, Germany . AiCuris is devoted to research and clinical development of novel, resistance-breaking drugs for the treatment of viruses like Cytomegalovirus (HCMV), Herpes Simplex, Hepatitis B, HIV and Hepatitis C as well as for resistant Gram positive and Gram negative bacterial infections in hospitals. Furthermore, the portfolio comprises two immune modulators.
Link to the high resolution picture: http://www.aicuris.com/images/dsc_0168.jpg
AiCuris GmbH & Co. KG
Friedrich-Ebert-Str. 475/Building 302
Phone +49 202 317 63 1176
Fax +49 202 317 63 1177